CUE
Cue Biopharma, Inc.
Healthcare · Biotechnology · NCM
$29.46
Data: 2026-05-15
✓ ETHICAL PASS

MOAT
HIGH
Data Confidence: 85.7%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$75M
Total market value of the company
Trailing P/E
N/A
Forward P/E
-47.85
Based on estimated future earnings — lower means cheaper
Rev Growth
+1,292.3%
Year-over-year revenue change
Profit Margin
-96.9%
How much profit the company keeps from each dollar of revenue
ROE
-121.1%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$115.00
+290% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 1 analysts covering this stock
About Cue Biopharma, Inc.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

https://www.cuebiopharma.com

Country: United States Employees: 29 Industry: Biotechnology
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
4.4% PASS
Debt must be below 33% of total assets
Cash Ratio
29.5% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKUP
Price trending up with increasing momentum
Sharpe Ratio
0.393
Positive but modest risk-adjusted returns
Kelly Fraction
0.0124
Marginal edge — very small allocation suggested
Calmar Ratio
-0.398
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-36.0%
Historical annualised return based on price data
Max Drawdown
-90.5%
Largest peak-to-trough decline — the worst it has been
HMM State
BEAR
Statistical model detects bearish conditions
Days in State
16
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
2.39
Significantly more volatile than the market
52W High
$41.42
29% below the year high
52W Low
$4.98
492% above the year low
Avg Volume
744,651
Average daily shares traded — higher means easier to buy and sell
Short Ratio
0.3
Days it would take all short sellers to cover — higher means more crowded
Short % Float
8.9%
Moderate short interest
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-8.40
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.16
Conservative use of debt — low financial risk
Current Ratio
2.74
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
2.64
Like current ratio but excludes inventory — stricter test
Gross Margin
-26.9%
Revenue left after cost of goods — higher means pricing power
Operating Margin
8.9%
Profit from core operations before interest and tax
Free Cash Flow
$-9,951,750
Negative — the business is spending more than it generates
Revenue (TTM)
$27M
Total revenue over the last 12 months
Net Income
$-26,602,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
1
Target High
$115.00
Target Median
$115.00
Target Low
$115.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2025-12-30 SARRAF PASHA Director 323,857 $99,747
2024-12-16 PASSERI DANIEL R Chief Executive Officer 30,000 $30,900
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.